Mavacamten
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Conditions
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Trial Timeline
Sep 4, 2025 → Dec 13, 2027
NCT ID
NCT07004972About Mavacamten
Mavacamten is a approved stage product being developed by Bristol Myers Squibb for Symptomatic Obstructive Hypertrophic Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07004972. Target conditions include Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07361289 | Pre-clinical | Recruiting |
| NCT07004972 | Approved | Recruiting |
| NCT07383025 | Pre-clinical | Recruiting |
| NCT06146660 | Pre-clinical | Recruiting |
| NCT06338202 | Pre-clinical | Completed |
| NCT06551129 | Pre-clinical | Recruiting |
| NCT06549608 | Pre-clinical | Active |
| NCT06112743 | Approved | Active |
| NCT07107373 | Pre-clinical | Active |
| NCT05939700 | Pre-clinical | Recruiting |
| NCT06023186 | Pre-clinical | Recruiting |
| NCT07168655 | Pre-clinical | Completed |
| NCT05719805 | Phase 1 | Completed |
| NCT05582395 | Phase 3 | Completed |
| NCT05414175 | Phase 3 | Completed |
| NCT05362045 | Phase 1 | Completed |
| NCT04766892 | Phase 2 | Completed |
| NCT03723655 | Phase 2/3 | Completed |
| NCT03496168 | Phase 2 | Completed |
Competing Products
20 competing products in Symptomatic Obstructive Hypertrophic Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sodium hyaluronate + placebo injection | Daiichi Sankyo | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Aficamten + Placebo | Sanofi | Phase 3 | 76 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |